Jade Biosciences posts Q2 2025 earnings release

Jade Biosciences, Inc. filed a current report to note that it issued a press release announcing its financial results for the quarter ended June 30, 2025.

Rhea-AI Filing Summary

Jade Biosciences, Inc. filed a current report to note that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The company states that the press release, included as Exhibit 99.1, provides details of these quarterly results.

The company clarifies that the earnings press release and related disclosure are being furnished, not filed, which means they are not subject to certain liability provisions of the securities laws and are not automatically incorporated into other SEC filings.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jade Biosciences, Inc. (JBIO) disclose in this 8-K?

Jade Biosciences, Inc. disclosed that it issued a press release announcing its financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1.

Which financial period does Jade Biosciences (JBIO) cover in this report?

The report refers to Jade Biosciences, Inc.'s financial results for the quarter ended June 30, 2025.

How are the Jade Biosciences (JBIO) earnings materials treated under securities laws?

The earnings information in Item 2.02 and Exhibit 99.1 is being furnished to the SEC, not filed, and therefore is not subject to Section 18 liability or automatically incorporated into other Securities Act or Exchange Act filings.

What exhibits are included with this Jade Biosciences (JBIO) 8-K?

The 8-K includes Exhibit 99.1, the press release issued on August 13, 2025, and Exhibit 104, the cover page interactive data file embedded within the inline XBRL document.

Who signed the Jade Biosciences, Inc. (JBIO) 8-K?

The report was signed on behalf of Jade Biosciences, Inc. by Tom Frohlich, the company's Chief Executive Officer.

On what date did Jade Biosciences (JBIO) issue the earnings press release?

Jade Biosciences, Inc. issued the earnings press release on August 13, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/13/2025 - 04:14 PM EDT Learn about SEC filing dates

NASDAQ false 0001798749 0001798749 2025-08-13 2025-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

Jade Biosciences, Inc.

(Exact name of Registrant as specified in its charter)

Nevada		001-40544		83-1377888
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

221 Crescent St., Building 23 Suite 105 Waltham, MA		02453
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 312-3013

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		JBIO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02. Results of Operations and Financial Condition.

On August 13, 2025, Jade Biosciences, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”).

This Item 2.02 and Exhibit 99.1 to this Report are being furnished to the SEC and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are being furnished herewith:

EXHIBIT INDEX

Exhibit		Description
99.1		Press release issued on August 13, 2025.
104		Cover page interactive data file (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Jade Biosciences, Inc.
				(Registrant)
Date: August 13, 2025				By:		/s/ Tom Frohlich
				Name:		Tom Frohlich
				Title:		Chief Executive Officer